NCT07489521 Arthrosamid vs. Steroid for the Management of Knee Osteoarthritis
| NCT ID | NCT07489521 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Cappagh National Orthopaedic Hospital |
| Condition | Osteo Arthritis Knee |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-01-29 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 200 participants in total. It began in 2026-01-29 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will be a randomised control trial of the use of intra-articular Arthrosamid® a novel intraarticular hydrogel vs. standard of care (steroid and local anaesthetic) for the non-operative management of knee osteoarthritis.
Eligibility Criteria
Inclusion Criteria: * Adults * Symptomatic single side knee pain. * Patients with diagnosis of knee osteoarthritis radiographic Kellgren and Lawrence system OA grade II-III-IV on x ray or MRI. Exclusion Criteria: * Inflammatory conditions, * Cancer, * acute infection, * pregnancy and breastfeeding. * Uncontrolled diabetes mellitus, * Joint diseases in the knee, such as rheumatoid arthritis or gout, history of knee surgery with metallic implant. * If patient has undergone knee arthroscopy in past 6 months. * Intra-articular injection of corticosteroids during the previous 3 months, intra-articular injection of other drugs, such as hyaluronic acid over the previous 1 year. * Contraindications for intra-articular injection, such as thrombocytopenia, coagulopathy, articular infection of knee, impairment of immunity.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07489521 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Osteo Arthritis Knee. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07489521 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07489521 currently recruiting?
Yes, NCT07489521 is actively recruiting participants. Contact the research team at seantee.lim@nohc.ie for enrollment information.
Where is the NCT07489521 trial being conducted?
This trial is being conducted at Dublin, Ireland.
Who is sponsoring the NCT07489521 clinical trial?
NCT07489521 is sponsored by Cappagh National Orthopaedic Hospital. The trial plans to enroll 200 participants.